Novartis’ Afinitor Disperz Wins New TSC-Related Approval

Roquette, the France-based supplier of plant-based ingredients for food, nutrition and health markets, has launched two new wheat-free directly compressible grades of Mannitol/a>. Mumbai-based Signet Chemical Corporation Pvt. Ltd. is the authorised distributor for the products in India.
The company has been investing in excipient innovation for the growing nutraceutical industry. It is seeking to address the growing consumer preference for clean label products like natural, organic, allergen-free, where in gluten-free products are also being increasingly preferred by consumers in general and particularly by those with dietary restrictions or celiac diseases.
According to Roquette, the two new grades – Pearlitol SW-F 100 and Pearlitol SW-F 200 – have comparable direct compression performance as that of Pearlitol 100 SD and Pearlitol 200 SD (spray-dried mannitol) grades, which are the preferred excipients due to properties like optimum flow, compressibility, high chemical compati-bility and non-hygroscopicity. Spray-dried mannitol is soluble in nature, has absence of unstable crystalline form and also has a negative heat of solution, which gives a cooling effect and pleasant taste to nutraceutical tablets.
Roquette offers a broad range of natural, functional filler/binder and taste-masking excipients that provide pleasant taste, mouth-feel and solid or liquid oral dosage form choice (syrup, lozenge, ODT, ODF, effervescent, gummy). With three innovation centres across the globe, Roquette is continuously investing in designing multi-functional excipients and ready to use co-processed platforms to meet customer needs. The company has leveraged its secure global supply chain and scale-up competency in spray-drying to innovate new solutions and have strengthened their position in the nutraceutical industry. Products formulated with the new Pearlitol SW-F grades can be claimed to be gluten-free, tooth-friendly, sugar free and non-GMO, it said.
2026-10-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Novartis Reports Strong Q3 2023 Financial Results, Driven by Key Blockbuster Drugs
-
Novartis sells 5 products
-
The multinational pharmaceutical company plans to sell its business
-
Novartis Sandoz Launches First Esbriet Generic in US
-
Novartis Suspends Production of Two Radioligand Drugs Due to Potential Quality Issues
-
The Most Expensive Drug in The World! Novartis' SMA Gene Therapy Zolgensma Strengthens Its Performance And Is About to Land in China
-
Novartis Global Restructuring To Cut Thousands of Jobs
-
Novartis' Canakinumab in NSCLC Phase 3 Trial Fails Again
-
Novartis has the most new drugs approved, and Roche's new drugs have the highest value!
-
Top 10 most expensive drugs in the world: Novartis gene therapy drugs rank first
Recommend Reading
-
Ineos Rescues UK's Last Dichloroethane Plant
-
Brazil’s SISPA Platform Signals a New Phase in Pesticide Registration
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
BASF Ludwigshafen Workforce Falls Below 30,000, Lowest Level in 72 Years
-
Coke market prices show strong performance in China
-
Business Society’s Acrylonitrile Trend Analysis for September 14, 2026: Anti-Depreciation Alert
-
Business Society’s Market Outlook for Hydrofluoric Acid on September 3, 2026: Volatile but Generally Strong Trend
-
Terminal demand weak, adipic acid market trend declines
-
Business Society PVC Trend Analysis for September 14, 2026: High-Range Fluctuations